The overall number of somatic point mutations and small indels was similar in TP53-mutated myeloid malignancies and CBF AML samples (Figure 2), and neither the mutation spectrum nor signatures suggested recurrent differences in mutational processes (Supplementary Figure 1). This evidence concerns the gene TP53 and acute myeloid leukemia.